A place of silodosin in the treatment of LUTS/BPH according to evidence-based medicine and real clinical practice
- Authors: Kotov S.V1, Bogdanov D.A1
-
Affiliations:
- Pirogov Russian National Research Medical University
- Issue: No 5 (2021)
- Pages: 94-98
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312705
- DOI: https://doi.org/10.18565/urology.2021.5.94-98
- ID: 312705
Cite item
Open Access
Access granted
Abstract
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are common disorder in older men. The mainstay of conservative treatment for BPH is a1-adrenoblockers. A review of the literature on silodosin, a selective α-adrenergic blocker, is discussed in the article. In clinical studies, there was a significant improvement in IPSS scores and maximum urinary flow rate in patients who received silodosin at a daily dose of 8 mg compared to those receiving placebo. It should be noted that silodosin has demonstrated long-term safety and early onset of efficacy. Compelling literature data to support the clinical benefit of silodosin for the treatment of LUTS associated with BPH is presented.
Keywords
Full Text
About the authors
S. V Kotov
Pirogov Russian National Research Medical University
Email: urokotov@mail.ru
Ph.D., MD, professor, Head of the Department of Urology and Andrology
D. A Bogdanov
Pirogov Russian National Research Medical Universityresident at the Department of Urology of Medical faculty
References
- Пушкарь Д.Ю., Раснер П.И., Бормотин А.В., Васильев А.О. Комбинированная терапия доброкачественной гиперплазии предстательной железы. Методические рекомендации № 17 М., ИД «АБВ-пресс», 2019. 8 с.
- Roehrborn C.G., Cruz F., Fusco F. а1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different? Adv Ther. 2017;33( 12):2110-2121. Doi: 10.1007/ s12325-016-0423-5.
- Chapple C.R., Montorsi F., Tammela T.L., Wirth M., Koldewijn E., Fernandez Fernandez E. European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, doubleblind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 201;59(3):342-352. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10. PMID: 21109344.
- Alcantara-Montero A. Experience with silodosin in «real life» (SiRE study). Actas Urol Esp. 2016;40(8):534-535. English, Spanish. doi: 10.1016/j.acuro.2016.03.004. Epub 2016 Apr 25. PMID: 27126124.
- Takahashi H., Kubono S., Taneyama T., Kuramoto K., Mizutani H., Tanaka N., Yoshida M. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study. Drugs R. D. 2019; 19(1):47-55. doi: 10.1007/s40268-018-0258-4. PMID: 30607819; PMCID: PMC6380964.
- Yamanishi T., Kaga K., Fuse M., Shibata C., Kamai T., Uchiyama T. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal? Int J. Urol. 2015;22( 12): 1143- 1148. doi: 10.1111/iju.12915. Epub 2015 Aug 27. PMID: 26310102.
- Creta M., Cornu J.N., Roehrborn C.G., Finazzi Agro E., Montorsi F., Longo N., Imperatore V., De Sio M., Arcaniolo D., Mirone V., Fusco F. Clinical Efficacy of Silodosin in Patients with Severe Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction: A Pooled Analysis of Phase 3 and 4 Trials. Eur Urol Focus. 2021;7(2):440-443. Doi: 10.1016/j. euf.2020.01.014. Epub 2020 Feb 10. PMID: 32057739.
- Fusco F., Creta M., Imperatore V., Longo N., Imbimbo C., Lepor H., Mirone V. Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies. Adv Ther. 2017;34(4):773-783. doi: 10.1007/s12325-017-0504-0. Epub 2017 Mar 2. PMID: 28255867.
- Seki N., Takahashi R., Yamaguchi A., Ito K., Takayama K., Nanri K., Kamiryo Y., Yamashita H., Komine S., Miyazaki Y., Uozumi.J., Naito S. Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study. Int J. Urol. 2015;22(3):311-336. doi: 10.1111/iju.12680. Epub 2015 Jan 18. PMID: 25597862.
- Gul A., Coban S., Turkoglu A.R., Guzelsoy M., Ozturk M., Kankilic N.A. Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity. Prostate Int. 2020;8(4): 152-157. doi: 10.1016/j.prnil.2020.04.002. Epub 2020 May 19. PMID: 33425792; PMCID: PMC7767940.
- Kumar S., Tiwari D.P., Ganesamoni R., Singh S.K. Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology. 2013;82(1):171- 175. doi: 10.1016/j.urology.2013.02.020. Epub 2013 Apr 3. Erratum in: Urology. 2014;84(4):990. PMID: 23561712.
- Homma Y., Kawabe K., Takeda M., Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology. 2010;76(6): 1446-1450. Doi: 10.1016/j. urology.2010.03.015. Epub 2010 May 15. PMID: 20472263.
- Montorsi F., Gandaglia G., Chapple C., Cruz F., Desgrandchamps F., Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). Int J. Urol. 2016;23(7):572-579. doi: 10.1111/iju.13088. Epub 2016 Mar 11. PMID: 26969887.
- Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 98 p.
- Kumar S., Jayant K., Agrawal M.M., Singh S.K., Agrawal S., Parmar K.M. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology. 2015;85(1):59-63. doi: 10.1016/j.urology.2014.09.022. PMID: 25530364.
Supplementary files
